FADD amplification in lung cancer promotes G1 to S cell cycle transition – UROP Spring Symposium 2021

FADD amplification in lung cancer promotes G1 to S cell cycle transition

Aalaynah Nathoo


Pronouns: she/ her/hers

Research Mentor(s): Alnawaz Rehemtulla, Professor
Research Mentor School/College/Department: Radiation Oncology, Michigan Medicine
Presentation Date: Thursday, April 22, 2021
Session: Session 1 (10am-10:50am)
Breakout Room: Room 12
Presenter: 2

Event Link


Glioblastoma multiforme (GBM) is the most malignant primary central nervous system tumor and once diagnosed, the patient outcome does not look good. Currently, there are no curative treatment options for GBM, and the survival rate of patients diagnosed with the disease remains low. RAD51 is highly expressed in response to radiation and chemotherapy which is required for DNA repair from after these genotoxic therapies. Using small molecule drugs that modulate the RAD51 function, we have shown that they enhance chemo- and radio-sensitization in GBM due to inhibition of DNA repair. My UROP project will involve the purification of RAD51 protein so that the binding site and mechanism by which the RAD51 targeted drugs function can be delineated using X-ray crystallography. We hypothesize that the inhibition of RAD51 will sensitize GSCs to radio and chemotherapy which will further improve the survival of GBM patients. Although there are currently no results, this research and experiment is valuable because there are no effective therapies for GBM.

Authors: Alnawaz Rehemtulla, Aalaynah Nathoo, Sahezeel Awadia
Research Method: Laboratory Research

lsa logoum logo